| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/11/2011 | CA2440172C Itraconazole solution |
| 01/11/2011 | CA2439756C Substituted aminodicarboxylic acid derivatives with pharmaceutical properties |
| 01/11/2011 | CA2436891C Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors |
| 01/11/2011 | CA2430124C Lactam compounds and pharmaceutical use thereof |
| 01/11/2011 | CA2429781C Linkable sialyl lewis x analogs |
| 01/11/2011 | CA2422054C Bicyclic heteroaromatic compounds |
| 01/11/2011 | CA2420592C Fused pyrrolocarbazoles against inflammation |
| 01/11/2011 | CA2411778C Organic compounds |
| 01/11/2011 | CA2407593C Fused heteroaryl derivatives |
| 01/11/2011 | CA2404387C Theanine compositions for promoting sleep |
| 01/11/2011 | CA2400486C Aniline-derived ligands for the thyroid receptor |
| 01/11/2011 | CA2387095C Compound with growth hormone releasing properties |
| 01/11/2011 | CA2385592C Benzamides and related inhibitors of factor xa |
| 01/11/2011 | CA2378883C Methods of reducing microbial resistance to drugs |
| 01/11/2011 | CA2374039C Multiparticulate controlled release selective serotonin reuptake inhibitor formulations |
| 01/11/2011 | CA2372063C Pyridopyranoazepine derivatives, their preparation and their therapeutic application |
| 01/11/2011 | CA2349406C Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| 01/11/2011 | CA2328990C N,n-disubstituted amides that inhibit the binding of integrins to their receptors |
| 01/11/2011 | CA2309541C Vegi, an inhibitor of angiogenesis and tumor growth |
| 01/11/2011 | CA2156360C Adhesion receptor antagonists |
| 01/10/2011 | CA2709624A1 Immediate release dosage form of bosentan and process of manufacturing such |
| 01/10/2011 | CA2671778A1 Immediate release dosage form of bosentan and process of manufacturing such |
| 01/10/2011 | CA2671320A1 .beta.-phenylethylidenehydrazine derivatives |
| 01/06/2011 | WO2011003103A2 Pharmacology of visual cycle modulators |
| 01/06/2011 | WO2011003091A1 Compositions comprising finafloxacin and methods for treating ophthalmic, otic, or nasal infections |
| 01/06/2011 | WO2011003074A1 Non-sedating antihistamine injection formulations and methods of use thereof |
| 01/06/2011 | WO2011003071A1 Methods of modulating hepatitis c virus infection |
| 01/06/2011 | WO2011003065A2 Pyrazolopyrimidine jak inhibitor compounds and methods |
| 01/06/2011 | WO2011003064A2 Methods of treating neuropathic pain |
| 01/06/2011 | WO2011003045A1 Slow release magnesium composition and uses thereof |
| 01/06/2011 | WO2011003025A1 Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
| 01/06/2011 | WO2011003021A1 Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| 01/06/2011 | WO2011003018A2 Halogenated 2-deoxy-lactones, 2'-deoxy--nucleosides, and derivatives thereof |
| 01/06/2011 | WO2011003012A1 Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof |
| 01/06/2011 | WO2011003007A1 Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| 01/06/2011 | WO2011003005A1 Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof |
| 01/06/2011 | WO2011002995A1 Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, methods of making and use thereof |
| 01/06/2011 | WO2011002991A1 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
| 01/06/2011 | WO2011002984A1 Substituted phenoxypropylcycloamine derivatives as histamine-3 (h3) receptor ligands |
| 01/06/2011 | WO2011002953A2 Topical skin treatment kits |
| 01/06/2011 | WO2011002951A1 Compositions for treating bacterial infections |
| 01/06/2011 | WO2011002939A1 Chromium complexes as enhancers of brain glucose transporters |
| 01/06/2011 | WO2011002917A1 Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as a2a r agonists |
| 01/06/2011 | WO2011002910A1 Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 01/06/2011 | WO2011002891A1 A method of treatment of a neurological disorder |
| 01/06/2011 | WO2011002889A1 Improved formulation for nonsurgical exogenous crosslink therapy |
| 01/06/2011 | WO2011002887A1 FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS |
| 01/06/2011 | WO2011002852A2 Pro-drug complexes and related methods of use |
| 01/06/2011 | WO2011002817A1 Therapeutic compounds and compositions |
| 01/06/2011 | WO2011002816A1 Therapeutic compositions and related methods of use |
| 01/06/2011 | WO2011002808A1 Hcv protease inhibitors and uses thereof |
| 01/06/2011 | WO2011002807A1 Hcv protease inhibitors and uses thereof |
| 01/06/2011 | WO2011002776A1 Pharmaceutical formulations for iontophoretic delivery of an immunomodulator |
| 01/06/2011 | WO2011002772A1 Imidazopyridine derivatives and pbk inhibitors containing the same |
| 01/06/2011 | WO2011002708A1 Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents |
| 01/06/2011 | WO2011002702A1 Pharmaceutical tablet containing a liquid filled capsule |
| 01/06/2011 | WO2011002696A1 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid |
| 01/06/2011 | WO2011002624A1 Substituted 4-hydroxypyrimidine-5-carboxamides |
| 01/06/2011 | WO2011002623A1 Substituted 4-hydroxypyrimidine-5-carboxamides |
| 01/06/2011 | WO2011002606A1 Methods of identifying a patient population eligible for treatment with nitric oxide via inhalation |
| 01/06/2011 | WO2011002584A1 Treatment of hepatitis c virus infections |
| 01/06/2011 | WO2011002525A1 Methods for treatment of muscular dystrophy |
| 01/06/2011 | WO2011002523A1 Phosphorus containing quinazoline compounds and methods of use |
| 01/06/2011 | WO2011002520A2 Small molecule inhibitors of parp activity |
| 01/06/2011 | WO2011002425A2 Pharmaceutical composition increasing solubility and stability |
| 01/06/2011 | WO2011002423A2 Solubility enhancing pharmaceutical composition |
| 01/06/2011 | WO2011002415A1 Synthesis and use of fluorophore-tagged antimalarials |
| 01/06/2011 | WO2011002409A1 5h-pyrrolo[3,4-£>]pyrazin-7-amine derivatives inhibitors of beta-secretase |
| 01/06/2011 | WO2011002408A1 Novel compounds for treatment of neurodegeneration associated with diseases, such as alzheimer's disease or dementia |
| 01/06/2011 | WO2011002407A1 Novel compounds for treatment of neurodegeneration associated with diseases, such as alzheimer's disease or dementia |
| 01/06/2011 | WO2011002405A1 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 |
| 01/06/2011 | WO2011002258A2 Arginine-based amphiphilic peptide micelle |
| 01/06/2011 | WO2011002184A2 Phosphoric acid ester of bicalutamide for treating prostate cancer |
| 01/06/2011 | WO2011002161A2 Transdermal composition comprising tolterodine |
| 01/06/2011 | WO2011002100A1 Medicament for the long term nsaid use |
| 01/06/2011 | WO2011002067A1 Heterocyclic compound and use thereof |
| 01/06/2011 | WO2011002033A1 Glucose metabolism-improving agent and glucose metabolism-improving composition |
| 01/06/2011 | WO2011002026A1 Amyloid fibril formation inhibitor and use thereof |
| 01/06/2011 | WO2011002012A1 Medicinal agent comprising combination of sglt1 inhibitor and insulin-resistance-ameliorating agent |
| 01/06/2011 | WO2011002011A1 Combined medicine of sglt1 inhibitor and dpp-iv inhibitor |
| 01/06/2011 | WO2011002001A1 Combined medicine of pyrazole derivative and biguanide drug |
| 01/06/2011 | WO2011001954A1 Therapeutic agent for abnormal defecation in inflammatory bowel disease patient who is in remission phase |
| 01/06/2011 | WO2011001951A1 Ophthalmic composition |
| 01/06/2011 | WO2011001931A1 Novel oxadiazole derivative |
| 01/06/2011 | WO2011001913A1 Ppar ligand |
| 01/06/2011 | WO2011001897A1 Medicinal agent and method for treatment of intractable chronic hepatitis c |
| 01/06/2011 | WO2011001676A1 Surface anesthetic agent |
| 01/06/2011 | WO2011001634A1 Method for improving bioavailability of latanoprost |
| 01/06/2011 | WO2011001450A1 Stable oral pharmaceutical composition comprising atorvastatin |
| 01/06/2011 | WO2011001441A1 A composition of extract of emblica officinalis and method of preparing the same |
| 01/06/2011 | WO2011001440A1 Pharmaceutical compositions of valsartan |
| 01/06/2011 | WO2011001425A1 Local therapeutic release device |
| 01/06/2011 | WO2011001419A1 Covalent inhibition of bacterial quorum sensing |
| 01/06/2011 | WO2011001413A1 Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
| 01/06/2011 | WO2011001383A1 Crystalline form of fosamprenavir calcium |
| 01/06/2011 | WO2011001258A1 Compositions, methods, and kits for treating viral and bacterial infections by tocotrienols, tocomonoenols, tocodienols, tocopherols, and their derivates |
| 01/06/2011 | WO2011001214A1 Surface amorphization of phenprobamate |
| 01/06/2011 | WO2011001212A1 Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation |
| 01/06/2011 | WO2011001202A1 Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application |
| 01/06/2011 | WO2011001169A1 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |